Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
Frequently asked questions
What sector does BerGenBio ASA (BRRGF) operate in?
BerGenBio ASA belongs to the Materials sector and operates in the Biotechnology industry.
What is BerGenBio ASA (BRRGF) current stock price?
As of the latest data, BerGenBio ASA stock price is $97.09, with a previous close of $97.09.
What is BerGenBio ASA (BRRGF) current market capitalization?
BerGenBio ASA market cap is approximately 434.83 million.
What is BerGenBio ASA (BRRGF) Earnings Per Share (EPS)?
The trailing EPS is -$204.13.
Does BerGenBio ASA (BRRGF) pay dividends?
No. BerGenBio ASA does not pay a dividend.
What is BerGenBio ASA (BRRGF) beta (volatility) score?
BerGenBio ASA has a beta of 1.194, meaning its volatility is roughly in line with the market.